Strengthening clinical development, regulatory submission and post-marketing surveillance through the acquisition of CRO and PMS businesses
First written in FY2025-H1. 2 of 3 entries say "Advanced", first in FY2025. Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1AdvancedAnnual report
「At ArkMS株式会社, the company is working to expand and strengthen CRO solutions, strengthen TSCS collaboration, and develop Ark Platform, a system that collects and utilizes data within the Group related to the limited distribution of specialty pharmaceuticals and other products. It is also making maximum use of AI to improve productivity and advancing initiatives to establish its management foundation.」
Following the consolidation of ArkMS as a subsidiary, the Group specified initiatives to strengthen functions including CRO solutions, TSCS integration, Ark Platform, a data platform for limited-distribution products, and productivity through the use of AI. - FY2025AdvancedAnnual report
「In September 2024, the Company acquired all shares of ArkMS Co., Ltd., a new company established through a company split (incorporation-type company split) of the CRO and PMS business conducted by INTAGE Healthcare Inc. The acquisition is expected to make a significant contribution to strengthening the clinical development, regulatory submission and PMS functions of the Group's total supply chain.」
The Group acquired all shares of ArkMS, advancing the strengthening of clinical development, regulatory submission and post-marketing surveillance functions across its total supply chain. - FY2025-H1First statedAnnual report
「Furthermore, in September 2024, we acquired all shares of ArkMS Co., Ltd. (head office: Toshima-ku, Tokyo), a newly established company formed through a company split involving Intage Healthcare Inc. (head office: Chiyoda-ku, Tokyo) in relation to its CRO and PMS businesses.」
The Group acquired all shares of ArkMS and incorporated its CRO and PMS businesses into the Group. It aims to strengthen its clinical development, regulatory submission and PMS functions.